Targeting Inflammation in Cardiovascular Risk: Efficacy and Safety of Oral NLRP3 Inhibitor Ruvonoflast
This Phase 1b trial demonstrates that oral NLRP3 inhibition with ruvonoflast markedly reduces systemic inflammatory biomarkers in obese individuals at elevated cardiovascular risk, with favorable safety and tolerability, supporting further clinical development.



















